Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/jptcp.v30i18.3500

A REVIEW ON THE IMPACT OF HUMAN GENETICS ON CARDIOVASCULAR DISEASE

Noor Subhani[1], Fatima Hussain[2], Talha Ghafoor Sial[3*]

[1]Cardiology department, Allama Iqbal Teaching Hospital, Dera Ghazi Khan - Pakistan
[2]Medicine Ward Scouts Medical Complex, Gilgit - Pakistan
[3*]Gastroenterology department, Ghurki Trust Teaching Hospital, Lahore - Pakistan

[*]**Corresponding Author:** Talha Ghafoor Sial
[*]Gastroenterology department, Ghurki Trust Teaching Hospital, Lahore - Pakistan
Email: talhasial429@gmail.com

Abstract
Globally, cardiovascular disease (CVD) is the leading cause of death. It is a highly heritable condition therefor for a long time; researchers have been attempting to explore the genetic fundamentals of it. Numerous risk factors that have been found to be closely linked to the onset of CVD have been identified. These, however, only account for a small portion of instances; hence, study into the underlying reasons of the unexplainable risk has moved to genomes and then genetics. According to many studies, there is a genetic component to CVD; nevertheless, identifying the specific genomic elements that contribute to the development of CVD has been more difficult than expected, with just a handful of those cases exhibiting Mendelian inheritance. While particular genetic variants linked to illness have been identified by genome-wide association studies (GWAS), the underlying biochemical pathways are just now starting to become clear. We must connect these relationships to the complex, multifaceted regulation of gene expression in order to completely comprehend the biological consequences of these interactions. Comprehending the relationship between the information encoded in DNA and the functioning of these regulating layers would facilitate the creation of more efficacious medicines, as well as improved prognoses for the onset of cardiovascular disease. The human body is made up of 3,100 million haploid base pairs and 6,200 million diploid base pairs. Yet, due to natural selection, typical genetic variations have little impact on diseases, but rare genetic variations likely to display significant effect size. Thus, it makes logical to split genetic differences to two categories according to rate of allele and scopes on diseases. We are aware that uncommon genetic variations in many important genes, particularly those related to fat, are clearly linked to an elevated likelihood of CVD, although an a polygenic menace score made up of public chromosomal distinctions seems to function very good in over-all people. This data can be utilized to identify new pharmaceutical targets in addition to risk categorization. We present the crucial and straightforward theory that human genetics is significant for cardiovascular illness as, it is a greatly transmissible feature in this article of review, and we think it will pave the way for precision therapy in this field**.**

Introduction
One of the leading causes of death worldwide is cardiovascular disease (CVD) [1]. It is contributed to a total of seventeen million accidental deaths in 2005, or thirty percent of worldwide fatalities [2]. More over nearly four million individuals die from it in Europe alone yearly, making it the primary

cause of mortality (48% in total) and the greatest burden of illness. The outlook for this is still disappointing in spite of significant improvements in medical medical care, consequently it is still vital to determine the fundamental mechanisms and potential methods for treatment. Although here is an apparent environmental component to cardiovascular disease, only a small portion of incidences are explained by the risk factors identified in epidemiological research (such as tobacco use, elevated cholesterol levels, and high blood pressure) [3]. The promise of genomics and genetics to uncover the molecular processes behind this issue progression and to explain scenarios that are not clearly linked to established risk factors has raised a great deal of hope. Countless large-scale population surveys that assisted in the definition of the traditional set of CVD risk factors have proven the substantial family component of CVD, which has long been acknowledged. Nevertheless, the fact that a number of other risk variables, including blood pressure, cholesterol, and diabetes, are also genetically controlled, complicates research on the heritability of CVD [4]. Numerous research projects have been undertaken in an effort to treat this illness. Epidemiological studies have been particularly helpful in improving our understanding of them. Different backgrounds in cardiovascular disease. For instance, the USA's Framingham Heart Study [2-4] and Japan's Hisayam Study[5,6] showed that smoking, high blood pressure, and cholesterol are just a few of the risk factors for Cardiovascular diseases . Despite the fact that epidemiological studies have identified numerous variables linked to heart and blood vessel malfunction, the relationships between those features and CVD have been in consistent. Randomized controlled trials have been carried out for the determination of factors that are linked with CVD [7-8] On the other hand, it is fair to take genetic factors into account in the experimental training of CVD, as recognized that it is an exceedingly inherited characteristic [9]. Studies have demonstrated that personal relic information functions rather well for CVD risk assessment, and it has long been thought of as a means to this end [10–12]. But "personal antiquity" a kind of binary feature that is challenging to determine mathematically. We can now readily determine the sequence of human DNA and identify genetic factor linked to the development of CVD thanks to recent advances in genetics [13].

To completely understand the role of genetics in CVD, we need to look beyond traditional Mendelian genetics and investigate the several interconnected levels that control the genome. We can detect individuals at high risk in their early years, develop protocol on the basis of their root causes, and find novel approaches of therapy by thoroughly studying the linkages between the genome of human and cardiovascular toxicities. Main facts about the role of human genetics in CVD are provided in this review article, along with guidance on how to use gain insight to our everyday medical practice.

If we talk about the human genome it contains 3,100 million haploid base pairs and 6,200 million diploid base pairs. Despite the fact that DNA has definitively established the human genome's sequence sequencing which is still undistinguishable. To better clarify the biotic roles of their protein products or RNA, a great deal of research must be done. What's more, new research indicates that the majority of the enormous amounts of non-coding DNA in the genome may be linked to biological processes such as gene expression regulation, organization of chromosome, and the governing signals epigenetic trait [14–16]. Generally speaking, rare genetic differences have a greater impact on disease than common genetic variations. This theory has a lot of supporting evidence when it comes to bodyweight [18].

The human genome as it exists is incomprehensible. In order to distinguish between uncommon and common genetic changes, an effective approach has been presented to explain the association between the disease and human genetic material [17]. It is easy to believe that one's body weight is an extremely heritable characteristic. In an association research we conducted to look at the genetic backgrounds connected with body weight, we found one exceedingly rare heritable differences among the same species whose influence on a person's mass is as much as seven kilogram / allele, while there are several public hereditary variations whose special effects on body mass are roughly hundred gram / allele. Infrequent genetic differences with an effect of seven kilogram are significant from a therapeutic perspective; while common genetic variations with an effect of approximately

100 g are inconsequential nevertheless such a "score" might be significant enough for our daily medical care if we are able to concatenate the impacts via numerous common genetic variants.

What about CVD? Are researchers and doctors drawn to this heritable trait with genetic information? Yes is the answer. According to epidemiological studies, family history information is strongly correlated with heart disease, indicating that the condition may be inherited. The level of heredity of this looks to be as extraordinary as roughly 50% based on information gathered in At win's study [19]. A recent medical recommendation on precautionary atherosclerotic coronary artery disease (ASCVD) in Japan strongly encourages reviewing everyday past details in light of the above information [20]. Inborn gross abnormalities are the most significant to be aware of among the many uncommon genetic diseases linked to elevated CVD risk. familial elevated cholesterol levels is produced due to mutations in the low-density lipoprotein, or LDL, receptor or its related gene produce which is one of the most significant disorders in this regard [21–26]. Tendon the presence of x severe elevations of LDL cholesterol (LDL-C), and early it is common in patients in familial elevated cholesterol levels .The general population's estimated prevalence of this condition is 1 in 300, despite its classification as a "rare" disease[27, 28]. More critically, if (ABCG5) showed elevated risk for CVD, patients with FHhave an exceptionally high risk for the condition [29-31]. Nevertheless, lipoproteins high in triglycerides have been linked to CVD [32, 33]. For instance, eight times augmented odds of CVD are present in 1 in two hundred and fifty persons with triglycerides due to a harmful sudden change in lipoprotein lipase (LPL) [34]. Furthermore, apolipoprotein A5 (APOA5) mutations that cause excessive triglycerides in 1 in 3,000 people also raise the risk of CVD by 4.5 times [35]. Persons with a specific polymorphism in single-nucleotide in lipids (a) (LPA), as (one in fifty individuals) demonstrated elevated serum Lipid (a) levels and increased chances of cardiovascular disease. These are definitive instances of congenital uncommon genetic abnormalities linked to heart failure (CVD) that are not treated, while statins can reduce their risk in the short term [29, 30]. As a result, we need to focus significantly more on FH detection. Apart from FH, it was discovered that people with an uncommon (one in thousand) harmful modification in the cassette ATP-binding subfamily member 5 [36].

Rare genetic variations can provide protection against cardiovascular disease (CVD) in a number of inherited conditions, in addition to "disorders" linked to a higher risk for it .mutated Apo - lipoprotein C3 (APOC3) has been linked to lower triglyceride levels in 1 in 150 people, who also had compact danger of Cardiovascular diseases (probabilities quotient = zero point sixty) [37]. Crucially, those who had APOC3 knocked out showed a considerable reduction in the postprandial rise in triglycerides [38]. Likewise, a decreased risk of cardiovascular disease (CVD) was seen in 1 in 300 people with concomitant hyperlipidemia due to a deleterious mutation in angiopoietin-like 3 (ANGPTL3) (odds ratio = 0.61 [39]. Furthermore, we've demonstrated that people with harmful mutations in the cholesterol ester transfer protein (CETP) had lower CVD risks, most likely as a result of lower Low density lipid proteins levels as opposed to higher amounts of high-density lipoprotein cholesterol [40]. Previously demonstrated, people have muted APOB have familial hypo-beta-lip proteinuria have significantly decreased CVD risks. This is likely due to lowered levels of dystrophy-containing APOB-containing lipoproteins, such as triglyceride and LDL[41]. Also, it was demonstrated that abnormal low levels LDL-C, patients with MTTP deficiency demonstrated a protective effect against a postprandial rise in residual lipoprotein [42]. Lastly, we are currently employing, an inhibitor for Nieman-Piecke C1-Like 1 (NPC1L12), and a pro-protein convertases substilisine/kalian form 9 (PCsSK9) blocking in our everyday clinical practice in line with the discoveries from human knok outs (43–45). It is noteworthy that a strong causal relationship exists between the outcome and the DNA variant. These discoveries have prompted the creation of innovative pharmaceutical treatments aimed at reducing cardiovascular disease (Table 1).

The impact of communal heritable changes on illness is often minimal, in divergence to uncommon genomic dissimilarities. Many routinely inherent variants linked to CVD have been found by genomewide association studies (GWAS)[46–48]. As a result, researchers have proposed that combining public inherent differences into a single score may be diagnostically helpful.2010 saw

the release of the first attempt to create an apolygenic risk score (PRS).Researchers employed a PRS centered on thirteen single nucleotide variant (SNV) linked to the European GWAS to investigate potential associations between the PRS and ASCV occurrences in separate cohorts. They discovered a strong correlation between the PRS and ASCV occurrences, but at the time they were unable to demonstrate the value of the correlation in receiving operated characters (R-O-C) and network reclassification advance studies [49]. Megaa etal raised the number of common genetic variations to 27 in 2015 in order to assess whether PRS classification performs better than traditional risk factors. They discovered that a PRS with 27 common genetic variants was higher than its cutoff [50]. Furthermore, we evaluated the predictive PRS power with twenty SNVs to one with 50 SNVs, and we discovered that the higher the number of SNVs, the more predictive power the PRS has, regardless of family history information [51) In addition, it was demonstrated that a PRS consisting of 12 SNVs linked to atrial fibrillation was strongly connected to ischemic stroke occurrences, most likely cardio embolic stroke [52]. Likewise, Kheraa et al. verified that a PRS that uses almost six million SNV to forecast ASCVD strongly related in a score-dependent manner with actual ASCVD events [53]. **Table 2** highlights the efforts made to use a PRS to forecast ASCV incidents. A few researches have been done thus far to see if a PRS is equally helpful among the people of south Asia. Independent of additional environmental factors, Haachiya et al. revealed that stroke episodes in the over-all people of Japan were linked to PRS (genome-wide), almost thirty five thousand public gene variants [54]. The Hesayaama conducted a prospective population-based study that was started in nineties to look into the prevalence of ASCVD in Kyushu Island which is a famous town in Japan. They used a genome-wide association study summary data from the Health Center–based approaching project and BioBank (Japan project) to assess the stroke-related events in this study. According to Wang et al., cardiovascular disease (CAD) was linked to an age-wide PRS involving more than five million common genetic variants in Bangladeshi and Indianan peoples [55]. It's interesting that they made entire genome-wide PR essentially using GWAS summary results from European ancestry. A set of whole-genome sequencing data from South Asian persons to compensate for ancestry was used by Sanda.

These findings indicate that a major factor contributing to diseases risk, especially in individuals of South Asian history, is the variation in genetic makeup can be measured by PRS. When matching the uppermost to lowermost quintiles across 3 independent study groups, we observed a 3.22–3.91-incorporate increase in risk by enhancing a polygenic score for blood and heart diseases. Furthermore, persons of South Asian descent residing in the United Kingdom, Bangladesh, and Asia showed a very consistent pattern of illness associations, with odds ratios/standard deviation increments varying from 1.58 to 1.66 in all three investigations. These findings imply that it is possible to transfer polygenetic levels transversely at different ecological events. ,Kooyama and coworkers , currently demonstrated that in detecting CAA among Japanese populations, a Tran's ethnic genome wide PRS performed better than an ethnicity-specific risk evaluation [56]. They included Japanese GWAS (mostly through Japanese BioBank , electro Cardiogram, and Bio bank (UK)in a Trans ethnic meta-analysis, and they created a Trans ethnic genome-wide PRS. Additionally, the most public hereditary variations with unimportant consequence demonstrated a reliable route of influence between European and Japanese ancestries.

PRS has been demonstrated to be a valuable tool for a variety of uses, in adding to threat classification further than conventional variables of clinical risk. First, statins appear to be considerably more beneficial for CVD in those with high PRS than in those with reduced CVD PRS [57]. That statins are equally beneficial across all classic subgroups, including gender, hypertension, and diabetes, is excellent news [58]. Furthermore, a healthy lifestyle is linked to a lower risk of CVD in persons with a high propensity for CVD, indicating that hereditary CVD risk may be mitigated by leading a healthy lifestyle. In [59]. it is a continuously distributed, normally distributed number that can be used to estimate risk regardless of the causal pathways. On the other hand, it should matter which factors lead to the PRS's elevation. For instance, anti-inflammatory drugs may be more effective in person A and lipid modification medications may be more beneficial in person B when two people are encountered whose high PRS but the source of the components is diverse

(e.g., person A has many risk genes and individual B has many risk the alleles in utilization of lipid). Furthermore, as previously shown, a certain activities may be linked to the balance of PRS. According to the PRS and its components, lifestyle and dietary patterns vary among areas and ethnic groups; hence, a greater quantity of data is required to clarify what constitutes "good" behavior within particular populations.

Furthermore, most GWAS carried out to far have employed logistic models, which are unable to account for the interaction relationships between genetic variations and an outcome and may be the cause of the phenomenon known as "missing heritability." The mean while more complex arithmetical prototypes is required to find these correlations, which might then be utilized as tools to create a PR that is more potent. Remember that there are mental illnesses connected to cardiovascular disease. Then, cascade screenings is a helpful technique to identify afflicted relatives at an early age. In the instance of FH, we have demonstrated that the prognosis of the afflicted relatives was substantially correlated with cascade screening for FH. Additionally, there is an instance where the existence of a specific kind of A pharmaceutical intervention modifies the effect of mutation [61].

Furthermore, we would like to underline that a significant number of patients showed a severe annual myocardial infarction linked to Phytosterolemia [62–66], currently thought to be significantly more common in the whole populace. Subsequent, the elevated PRS for CVD associated with common genetic variants appears to be consistent with inherited CVD risk within their family [67]. This implies that those with high PRS for CVD should be included in "cascade screening" for patients at greater threat. PRS for heart and blood vessels problems is linked to CVD regardless evidence of personal history. Mainly ASCVD was focused In this review study because they are also highly heritable features, the ideas we proved also applied to other cardiac phenotypes, such as aortic disease, the heart beat is abnormal, heart muscles disorder, [68–73].

Conclusion

It was concluded that CVD is a strongly transmissible condition. Common genetic variations and unusual genetic variations are helpful for cascade screening as well as risk stratification. Due to regular diagnosis and suitable interventions, genetic knowledge is not stigmatized. To include this significant component into our therapeutic practice, we must set up randomized controlled studies to ascertain the true use of such genetic information.

Table 1: New pharmacological interferences to lesser Low density lipid stages

Target	Absence or carriers of PT	Composites	Affected lipids	Mendelian randomization
Angiopoietin like protein	Familial united hypolipo proteinemia	**Evkeeza**	Lowered LDL-C and Triglycerides	Reference number 42
Apo lipoprotein B	Familial hypo –beta- lipo Pro- teinemia	Kynamro	Lowered LDL-C and Triglycerides	44 reference no
Apolipoprotein C	Insufficiency	Waylivra	Triglycerides lowered	37 reference no
Cholesteryl ester transfer protein	Insufficiency	Obicetrapib	HDL-C increases , LDL-C lowered	43 reference no
Microsomal triglyceride transfer protein	A beta lipoproteinemia	Juxtapid	Low density lipo protein -C lowered	NA
Niemann-Pick C1	Carriers (Heterozygous) (1/650 persons)	Zetia	Low density lipo protein -C dropped	38 reference no
Proprotein convertase subtilsin-kexin type 9	Familial hypobeta lipo proteinemia	Zetia	Low density lipoprotein -C dropped	39 reference no

Table 2: Studies of PRS for the prediction of CVD

Authors [reference] and year of publication	PRS	People	Results	Key consequences
RipattiSetal. [49 2011	13 SNV	Swedish Finnish and societies	Coronary heart disease	HR1.66 (94% CI1.34–2.04) Top vs. Lowest quintile (PRS
TadaHetal.[52 2015	12 SNV	Swedish societies	Ischemic stroke	H.R 1.23 (94 % CI 1.04–1.46) Upper vs. lowermost quintile (PRS
MegaJL etal.[50 2015	27 SNV	Swedish group	CHD	H.R1.66 (95% CI1.35–2.04) Top vs. Bottom quintile(PRS)
TadaH etal.[51 2016	27&50 SNV	Swedish group	CHD	HR 1.23 (94% CI 1.04–1.46) Top vs. bottom quintile (PRS)
Khera AVetal.[53 2019	6.6M SNV	UK Bio bank	CHD	H.R1.81 (94% CI1.22–1.47) Top vs. Lowest quintile(PRS)
HachiyaTetal.[54 2020	>350,000 SNV	Japanese ;(East Asian)	Stroke (Ischemic)	H.R1.70(94% CI1.48–1.94)for 27-SNV-PRSHR1.92(95% CI 1.67–2.20) for 50-SNV-PRSTop vs. Bottom quintile (PRS
Wang Metal.[55 2020	MSNV(6.6	UK Bio bank;(South East Asian	CHD	H.R 2.45 (94% CI 1.16–5.12) Topmost vs. bottom quintile (PRS)
Koyama Setal.[56] 2020	~1MSNV	Bio bank Japan; (East Asian)UK	CHD	O.R2.65(94% CI2.30–3.05)Top-10% vs. remaining90%

PRS (polygenic risk score) US (United States) UK (United Kingdom) HR (hazard ratio) CI (confidence interval) OR, (odds ratio) CVD (cardio vascular disease), SNV (single nucleotide variations) CHD (Coronary heart disease)

References

1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW,etal.Heart disease and stroke statistics- :are port from *the American heart association. Circulation 2021*;143:e254–743.
2. *Mahmood, Levy, VasanT*, WangTJ. The framingham heart study and the epidemiology of cardiovascular disease:a *historical perspective*. Lancet 2014; 383:999–1008
3. AnderssonC, Johnson AD, Benjamin EJ, Levy D, Vasan RS. 70-*year legacy of the* Framingham Heart Study. *Nat Rev Cardiol 2019*; 16:687–98
4. Ninomiya. Japanese legacy cohort studies: the Hisayama Study. J Epidemiol 2018;28:444–51
5. HondaT, Chen S, HataJ, Yoshida D,Hirakawa Y,Furuta Y,etal. Development and validation ofa risk prediction model for atherosclerotic cardiovascular Disease in Japanese adults :the Hisayama study. J AtherosclerThromb2021. doi:10.5551/jat.61960.
6. TadaH, UsuiS, SakataK, TakamuraM, Kawashiri MA. Challenges of precision Medicine for atherosclerotic cardiovascular disease based on human genome Information. J Atheroscler Thromb2021; 28:59.
7. TadaH, UsuiS, Sakata K, TakamuraM, KawashiriMA. Low-density lipoprotein Cholesterol level cannot be too low: considerations from clinical trials, human genetics, and biology AtherosclerThromb2020; 27:489–98.
8. TadaH, FujinoN, NomuraA, NakanishiC, HayashiK, TakamuraM, etal.Personalized medicine for cardiovascular diseases' HumGenet2021; 66:67–74.
9. WilliamsRR, HuntSC, HeissG, ProvinceMA, BensenJT, HigginsM, etal. Usefulness of cardiovascular family history data for population-based preventive Medicine and medical research (the health family tree study and the NHLBI family heart study).AmJ Cardiol2001; 87:129 35.
10. Lloyd-Jones DM, NamBH, SrD'AgostinoRB, Levy D, MurabitoJM, WangTJ, et al. Parental cardiovascular diseases a risk factor for cardiovascular disease in middle-aged adults: prospective study of parents and off spring.JAMA 2004; 291:2204–11.

11. Yeboah J, McClellandRL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, etal. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308:788–95.
12. MusunuruK, KathiresanS. Genetics of common, complex coronary artery disease.Cell2019; 177:132–45.
13. ElkonR, AgamiR. Characterization of noncoding regulatory DNA in the human genome.NatBiotechnol2017; 35:732–46.
14. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol2010; 28:1057–68.
15. McPhersonR, Tybjaerg-HansenA. Genetics of coronary artery disease.CircRes 2016; 118:564–78.
16. KathiresanS, Srivastava D. Genetics of human cardiovascular disease. Cell 2012; 148:1242–57.
17. TurcotV, Lu Y, Highl and HM, Schurmann C, Justice AE, Fine RS, et al. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet 2018; 50:26–41.
18. ZdravkovicS, WienkeA, PedersenNL, MarenbergME, YashinAI, De FaireU. Heritability of death from coronary heart disease:a36-yearfollow-up of20 966Swedishtwins. J Intern Med2002;252:247–54.
19. KinoshitaM, Yokote K, AraiH, Iida M, Ishigaki Y, Ishibashi S, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases2017.J AtherosclerThromb2018;25:846–984.
20. Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, etal. Guidelinesfor diagnosis and treatment of familial hypercholesterolemia 2017.J Atheroscler Thromb 2018; 25: 751–70.
21. TadaH, TakamuraM, KawashiriMA. Familial hypercholesterolemia: anarrative review on diagnosis and managements trategies for children and adolescents. Vasc Health Risk Manag 2021; 17:59–67.
22. Tada H, HoriM, NomuraA, HosomichiK, NoharaA, KawashiriMA, etal.A catalogofthe pathogenic mutations of LDL receptor gene in Japanese familial hyper cholesterolemia .J ClinLipidol2020; 14:346–51.
23. TadaH, KawashiriMA, NoharaA, Inazu A, MabuchiH, YamagishiM. Impact Of clinical signs and genetic diagnosis of familial hyper cholesterolaemiaonthe prevalence of coronary artery disease in patients with severe hyper cholesterolaemia. EurHeartJ 2017; 38:1573–9.
24. Tada H, OkadaH, NomuraA, UsuiS, Sakata K, NoharaA, et al. Clinical diagnostic criteria of familial hypercholesterolemia - a comparison of the Japan atherosclerosis society and Dutch lipid clinic network criteria. CircJ 2021; 85:891–7.
25. TadaH, ShibayamaJ, NishikawaT, OkadaH, NomuraA, UsuiS, etal. Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemiain aJapanese community. Pract Lab Med2020; 22:e00181.
26. BeheshtiSO, MadsenCM, VarboA, NordestgaardBG. Worldwide prevalence of familial hypercholesterolemia: meta-analysesof11millionsubjects.J AmColl Cardiol2020; 75:2553–66.
27. HuP, DharmayatKI, Stevens CAT, Sharabiani MTA, Jones RS, WattsGF, et al. Prevalence of familial hypercholesterolemiaamong the general population and patients with atherosclerotic cardiovascular disease: systematic reviewandmeta-analysis.Circulation2020;141:1742–59.
28. Luirink IK, WiegmanA, Kusters DM, HofMH, Groothoff JW, de GrootE, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. NEnglJ Med2019; 381:1547–56.
29. TadaH, OkadaH, NomuraA, NoharaA, YamagishiM, TakamuraM, etal.Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events' Clin Lipidol 2021;15:358–65.
30. NomuraA, EmdinCA, WonHH, PelosoGM, Natarajan, ArdissinoD, etal. Heterozygous ABCG5gene deficiency and risk of coronary artery disease.Circ Genom PrecisMed2020; 13:417–23.

31. TadaH, KawashiriMA. Genetic variations, triglycerides, and atherosclerotic disease AtherosclerThromb2019;26:128–31.
32. Tada H, Takamura M, KawashiriMA. Genomics of hypertriglyceridemia. Adv Clin Chem 2020;97:141–69.
33. KheraAV, WonHH, PelosoGM, O'DushlaineC, LiuD, StitzielNO, etal. Association of rare and common variation in the lipoprotein lipase gene with Coronary artery disease.JAMA 2017;317:937–46.
34. DoR, StitzielNO, WonHH, Jørgensen AB, DugaS, AngelicaMerliniP, etal.Exomes sequencing identifies rare LDL Rand APOA5 alleles conferring risk for myocardial infarction. Nature 2015; 518:102–6.
35. ClarkeR, PedenJF, HopewellJC, KyriakouT, Goel A, Heath SC, et al. Genetic variants associated with Lp(a)lipoprotein level and coronary disease. NEnglJ Med2009;361:2518–28.
36. CrosbyJ, PelosoGM, AuerPL, CrosslinDR, StitzielNO, LangeLA, etal.Loss-of–functionmutationsin APOC3,triglycerides,andcoronarydisease.NEnglJ Med 2014;371:22–31.
37. Saleheen D, NatarajanP, Armean IM, Zhao W, Rasheed A, Khetarpal SA, etal. Human knock out sandphenotypicanalysisin acohortwithahighrate ofconsanguinity.Nature2017;544:235–9.
38. Stitziel NO, Khera AV, WangX, Bierhals AJ, Vourakis AC, Sperry AE, etal. ANGPTL 3deficiency and protection against coronary artery disease Am CollCardiol2017;69:2054–63.
39. NomuraA, WonHH, KheraAV, Takeuchi F, Ito K, McCarthyS, et al. Protein-truncating variant satthe cholestery lester transfer protein gene and risk for coronary heart disease. Circ Res 2017;121:81–8.
40. PelosoGM, NomuraA, KheraAV, ChaffinM, WonHH, ArdissinoD, etal.Rare protein-truncating variants in APOB,lower low-density lipoprotein cholesterol, and protection against coronary heart disease.Circ Genom PrecisMed 2019;12:e002376.
41. KawashiriMA, Tada H, HashimotoM, Taniyama M, NakanoT, NakajimaK, etal. Extreme contras to fpost prandial lremnant-like particles for medin abetalipo proteinemia and homozygous familial hypobetalipoproteinemia.JIMD Rep 2015;22:85–94.
42. StitzielNO, WonHH, MorrisonAC, PelosoGM, DoR, etal., Myocardial Infarction Genetics Consortium Investigators Inactivating mutations in NPC1L1and protection from coronary heart disease. Engle Med2014;371:2072–82.
43. BennM, NordestgaardBG, GrandeP, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L,low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.J Am Coll Cardiol 2010;55:2833–42.
44. TadaH, OkadaH, NomuraA, NoharaA, TakamuraM, KawashiriMA. Ahealthy family of familial hypo beta lipopr oteinemia caused by a protein-truncating variant in the PCSK9gene.Intern Med2020; 59:783–7.
45. HowsonJMM, ZhaoW, BarnesDR, HoWK, YoungR, PaulDS, etal.Fifteen newriskloci for coronary artery disease highlight arterial-wall-specific mechanisms.NatGenet2017; 49:1113–19.
46. KlarinD, ZhuQM, EmdinCA, ChaffinM, HornerS, McMillanBJ, etal.Genetic analysisin UKBiobanklinks insulin resistance andtransendothelial migration pathwaysto coronaryarterydisease.NatGenet2017;49:1392–7.
47. vanderHarstP, VerweijN. Identification of 64 novel genetic loci providesan expandedviewonthegeneticarchitectureofcoronaryarterydisease.CircRes 2018;122:433–43.
48. RipattiS, TikkanenE, Orho-MelanderM, HavulinnaAS, SilanderK, SharmaA, etal. Amultilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses.Lancet2010;376:1393–400.
49. MegaJL, StitzielNO, SmithJG, ChasmanDI, CaulfieldM, DevlinJJ, etal.Geneticrisk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lance 2015; 385:2264–71.

50. TadaH, MelanderO, LouieJZ, CataneseJJ, RowlandCM, DevlinJJ, etal.Risk prediction by genetic risk scores for coronary heart disease is independent of self-reportedfamily history.EurHeartJ 2016;37:561–7.
51. TadaH, ShiffmanD, SmithJG, SjögrenM, LubitzSA, EllinorPT, etal.Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrialfibrillationandstroke.Stroke2014;45:2856–62.
52. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, etal. Genome-wide polygenic scores for common diseases identify individuals with riske quivalentto monogenicmutations.NatGenet2018;50:1219–24.
53. Hachiya T, Hata J, Hirakawa Y, Yoshida D, Furuta Y, Kitazono T, et al. Genome-wide polygenic score and the risk of ischemic stroke in a prospective cohort: the Hisayamastudy.Stroke2020;51:759–65.
54. WangM, MenonR, MishraS, PatelAP, ChaffinM, TanneeruD, etal.Validation of agenome- wide polygenic core for coronary artery disease in South Asians. J AmCollCardiol2020;76:703–14.
55. Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, MomozawaY, et al. Population-specific and trans-ancestry genome-wide analyses identify 238 H.Tada,N.Fujino,K.Hayashietal. Journal of Cardiology79 (2022) 233–239 distinct and shared genetic risk loci for coronary artery disease.NatGenet 2020;52:1169–77.
56. NatarajanP, Young R, Stitziel NO, Padmanabhan S, Baber U, MehranR, et al. Polygenic risk score identifies subgroup withhigher burden of atherosclerosis and greaterrelativebene fit from statintherapy in the primary preventionsetting.Circulation2017;135:2091–101.
57. BaigentC, BlackwellL, Emberson J, HollandLE, ReithC, et al., Cholesterol Treatment Trialists'(CTT) Collaboration Efficacyand safety ofmoreintensive lowering of LDL cholesterol: Ameta-analysis of data from 170,000participants in 26randomisedtrials. Lancet2010; 376:1670–81.
58. KheraAV, EmdinCA, DrakeI, NatarajanP, BickAG, CookNR, etal.Genetic risk, adherence to a healthy lifestyle, and coronary disease. NEngl J Med 2016;375:2349–58.
59. FahedAC, WangM, HomburgerJR, PatelAP, BickAG, NebenCL, etal.Polygenic background modifies penetrance of monogenic variants fortier1genomic conditions. Nat Commun2020; 11:3635.
60. Tada H, OkadaH, NomuraA, Takamura M, Kawashiri MA. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene.Lipids Health Dis2020;19:3.
61. Kawamura R, Saiki H, Tada H, HataA. Acute myocardialinfarction in a 25-year-old woman with sitosterolemia.J ClinLipidol2018;12:246–9.
62. Tada H, Nomura A, Nohara A, Inazu A, Mabuchi H, Yamagishi M, et al. Post-prandial remnant lipoprotein metabolism in sitosterolemia. J AtherosclerThromb2018;25:1188–95.
63. Tada H, NoharaA, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA. Sitosterolemia, hypercholesterolemia, and coronary artery disease. J Atheroscler
64. TadaH, OkadaH, NomuraA, YashiroS, NoharaA, Ishigaki Y, etal.Rareand deleterious mutation sin ABCG5/ABCG8genes contribute to mimickingand Worsening of familial hyper cholesterolemia phenotype. CircJ 2019;83:1917–24.
65. TanakaH, WatanabeY, HiranoS, TadaH, NomuraA, KawashiriMA, etal. Sitosterolemia exhibiting severe hyper cholesterolemia with tendon xantho mas due to compound heterozygous ABCG5 gene mutations treated with ezetimibeand alirocumab.Intern Med2020; 59:3033–7.
66. ReidNJ, Brockman DG, Leonard CE, PelletierR, Khera AV. Concordance of a High polygenic score among relatives: Implications for genetic counselingand cascade screening. Circ Genom Precis Med 2021; 14:e003262.
67. AkhtarT ,BandyopadhyayD, Ghosh RK, Mondal S. Left ventricular non compaction cardiomyopathy: Recent update on genetics, usefulness of biomarker, and speckle imaging. J

Cardiol2019; 73:94–5. [69] Nomura S. Genetic and non-genetic determinants of clinical phenotypes in cardiomyopathy.J Cardiol2019; 73:187–90.
68. WuJ, Sakaguchi T, Takenaka K, Toyoda F, Tsuji K, MatsuuraH, et al. A trafficking-deficient KCNQ1mutation, T587M, causes a severe phenotype of long QT syndrome by interfering with intracellular hERG transport. J Cardiol 2019; 73:343–50.
69. AibaT. Recent understanding of clinical sequencing and gene-based risks ratification in inherited primary arrhythmia syndrome Cardiol2019; 73:335–42.
70. TakedaN, KomuroI. Genetic basis of hereditary thoracic aortic aneurysms and dissections .J Cardiol2019; 74:136–43.
71. Mudd, J. O. and Kass, D. A.(2008). Tackling heart failure in the twenty-first century. Nature451, 919-928
72. Thanassoulis, G. and Vasan, R. S.(2010). Genetic cardiovascular risk prediction: will we get there? Circulation122, 2323-2334.
73. North, K. E., Howard, B. V., Welty, T. K., Best, L. G., Lee, E. T., Yeh, J. L., Fabsitz, R. R., Roman, M. J. and MacCluer, J. W.(2003). Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am. J. Epidemiol.157, 303-314